Abstract
The use of finerenone is now included in the 2022 revision to standard treatment guidelines for patients with type 2 diabetes and chronic kidney disease.Finerenone is a costly addition to standard treatment. Patients may need to receive prescription preauthorization from their insurer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
